Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01833455 · ClinicalTrials.gov registry record · Phase 2
Premature Ventricular Contractions (PVCs) and Blood Pressure Control
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01833455 is a Phase 2 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 8 participants.
The verdict
NCT01833455, a Phase 2 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if reduction in premature ventricular contraction (PVC) burden results in a decrease in blood pressure, sympathetic outflow, plasma catecholamines and an improvement in baroreflex gain. Flecainide will be used for PVC suppression in a randomized, double-blinded, crossover fashion.
Interventions
- DRUG PVC Suppression using Flecainide
- DRUG No PVC Suppression using Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-02 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01833455
The ClinicalTrials.gov registry entry for NCT01833455 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PVC Suppression using Flecainide is the first listed.
NCT01833455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01833455 about?
NCT01833455 is a clinical study titled "Premature Ventricular Contractions (PVCs) and Blood Pressure Control". The purpose of this study is to determine if reduction in premature ventricular contraction (PVC) burden results in a decrease in blood pressure, sympathetic outflow, plasma catecholamines and an improvement in baroreflex gain. Flecainide will be used for PVC suppression in a randomized, double-blin...
What is the current status of trial NCT01833455?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2013-02. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01833455?
The interventions under investigation include: PVC Suppression using Flecainide (DRUG), No PVC Suppression using Placebo (DRUG).
Who is sponsoring clinical trial NCT01833455?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.